ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Curonix Expands the Freedom® PNS System Patient Treatment Options with the Launch of its Innovative Wearable Solution for Chronic Pain of the Head, Neck, Shoulder, and Torso

POMPANO BEACH, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in opioid-free chronic pain relief, today announced the launch of its next-generation wearable accessory for the Freedom® Peripheral Nerve Stimulator (PNS) System. This innovative wearable targets chronic pain in the head, neck, shoulder, and upper torso regions, with the potential to serve up to 235,000 patients annually1.

This addition completes an already robust portfolio that provides physicians and patients with an effective solution for managing chronic pain and ensuring every targeted treatment area has a dedicated wearable, fulfilling Curonix’s mission to deliver the only full-body PNS system on the market.

Curonix’s wearable portfolio is designed for three core advantages: flexibility, versatility, and comfort through a slip-resistant, adjustable fit that accommodates a wide range of body types for consistent therapy delivery. With multiple configurations, a single wearable can precisely target nerve locations. The lightweight, low-profile designs support adhesive-free wear over clothing while maintaining therapy connectivity and power, ensuring comfort and confidence in daily activities.

“With more than 20,000 patients treated, the Freedom PNS System is helping patients regain control over their daily lives,” said Aure Bruneau, Chief Executive Officer of Curonix. “The addition of this innovative wearable completes the only full-body PNS portfolio, giving patients and physicians dedicated solutions for every major targeted peripheral nerve. By expanding our clinical reach while prioritizing patient comfort, we are broadening the potential of what PNS can achieve.”

The Freedom® PNS System has been cleared for use in the craniofacial region but is not yet commercially available.

For more information, visit curonix.com.

References:

  1. Data on file with Curonix


About Curonix LLC

Curonix LLC is a Delaware medical technology company dedicated to developing and commercializing innovative therapies intended to help relieve chronic pain. The proprietary Freedom PNS System is a non-integrated, minimally-invasive implant that does not include an implanted battery. The Freedom PNS System is powered by HF-EMC (High-Frequency Electromagnetic Coupling) and is comprised of a two-component implantable neurostimulator, an externally worn transmitter, and software used to set patient-specific stimulation programs. The two-component neurostimulator, comprised of an electrode array and a separate surgically connected receiver, is anchored within two separate incisions, including the creation of a subcutaneous pocket. The stimulation program is adjusted as needed to provide pain relief for the patient. For more information, visit curonix.com.

Contact Information:

Ashley Brown
Sr. Director of Marketing & Communications, Curonix
Ashley.Brown@curonix.com
512-791-4743

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/d857ab83-00fc-48b0-a997-85fac8a31671


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.